Drug
Abobotulinum Toxin A
Abobotulinum Toxin A: highest development phase Post-Market, developed by Ipsen. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Ipsen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Abobotulinum toxin A NCT03136341 | Post-Market | Tremor, Limb |
| Abobotulinum toxin A NCT02187679 | Not Applicable | Tourette Syndrome |
Latest
No recent events.
Follow Abobotulinum Toxin A on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.